In a recent phase III clinical trial including 557 patients with HER2-low BC, from which 63 had TNBC, those who had been treated with T-DXd showed longer progression free survival and overall survival compared to the patients treated with regular chemotherapy [15]. The gene discussed is ERBB2; the disease is breast cancer.